Tiziana Life Sciences (TLSA) Accumulated Expenses (2018 - 2025)
Tiziana Life Sciences (TLSA) posted quarterly Accumulated Expenses of $3.3 million for Q4 2025, up 99.21% year-over-year from $1.6 million in Q4 2024, and up 93.58% quarter-over-quarter from $1.7 million in Q2 2025.
Tiziana Life Sciences (TLSA) Accumulated Expenses (2018 - 2025) Analysis & Trends
Tiziana Life Sciences' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $3.3 million for Q4 2025.
- In Q4 2025, Accumulated Expenses rose 99.21% year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $3.3 million (up 99.21% YoY), while the FY2025 annual figure was $3.3 million, up 99.21% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $3.3 million, up from $1.7 million in the prior quarter.
- The five-year high for Accumulated Expenses was $3.3 million in Q4 2025, with the low at $816000.0 in Q2 2023.
- The 5-year median for Accumulated Expenses is $1.6 million (2022), against an average of $1.7 million.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses slumped 66.15% in 2022, then jumped 99.21% in 2025.
- Tiziana Life Sciences' Accumulated Expenses stood at $900000.0 in 2021, then soared by 74.44% to $1.6 million in 2022, then surged by 43.31% to $2.2 million in 2023, then fell by 26.67% to $1.6 million in 2024, then jumped by 99.21% to $3.3 million in 2025.
- Business Quant data shows TLSA's Accumulated Expenses at $3.3 million in Q4 2025, $1.7 million in Q2 2025, and $1.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tiziana Life Sciences | 133.66 Mn | 129.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.29 Mn |
| Jun 30, 2025 | 1.70 Mn |
| Dec 31, 2024 | 1.65 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Jun 30, 2023 | 816,000.00 |
| Dec 31, 2022 | 1.57 Mn |
| Jun 30, 2022 | 845,000.00 |
| Dec 31, 2021 | 900,000.00 |
| Jun 30, 2021 | 2.50 Mn |
| Dec 31, 2020 | 2.15 Mn |
| Jun 30, 2020 | 2.16 Mn |
| Dec 31, 2019 | 2.15 Mn |
| Jun 30, 2019 | 1.02 Mn |
| Dec 31, 2018 | 2.33 Mn |
| Jun 30, 2018 | 671,640.94 |